

Astellas Pharma Inc. (4503:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends

Company Report | 2024-11-22 | 88 pages | Quintel Research

AVAILABLE LICENSES:

- Single User Price \$175.00
- Multi User Price \$195.00
- Enterprise User Price \$225.00

Report description:

Report Summary

Year End Offer - Buy Now and get an updated version of this Report at no extra cost within 30 days of the release of Company's next Annual Report. (Offer expires on 31st Dec 2024)

Astellas Pharma Inc. (4503:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of Astellas Pharma Inc.'s business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Astellas Pharma Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Astellas Pharma Inc.'s strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Astellas Pharma Inc.'s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Astellas Pharma Inc.'s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Astellas Pharma Inc.'s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Astellas Pharma Inc. enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Astellas Pharma Inc. operates as a pharmaceutical company that manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. Astellas Pharma Inc. operates in the pharmaceuticals segment providing treatments for diseases like cancer, anemia, overactive bladder and also offers immunosuppressants.

Astellas Pharma Inc. offers pharmaceutical products and services including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Evrenzo for anemia, Betanis/Myrabetriq/BETMIGA for overactive bladder, and Prograf and Advagraf/Gracipor/ASTAGRAF XL as immunosuppressants. The company provides treatments for various diseases and conditions. Founded in 1923, the company is headquartered in Tokyo, Japan.

Astellas Pharma Inc. in the News:-

- 28-Oct-2024 - Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union
- 25-Oct-2024 - Every Day of Vision Loss Is One Too Many: Addressing the Impact of Eye Diseases
- 21-Oct-2024 - stellas' VYLOYTM (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
- 18-Oct-2024 - Silence, Stigma, and Misunderstanding: Our Mission to Break Down Barriers in Menopause
- 10-Oct-2024 - Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause

Scope

- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

it operates in.

Reasons to Buy

- Comprehensive Understanding of the Astellas Pharma Inc.'s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Astellas Pharma Inc.:

- Astellas Pharma Inc. Value Chain Analysis
- Astellas Pharma Inc. Porter's Five Forces Analysis
- Astellas Pharma Inc. VRIO Analysis
- Astellas Pharma Inc. BCG Analysis
- Astellas Pharma Inc. Segmentation, Targeting and Positioning (STP) Analysis
- Astellas Pharma Inc. Ansoff Matrix Analysis

Table of Contents:

Table of Contents

COMPANY EXECUTIVE SUMMARY 1

Table of Contents 2

Tables 6

Charts 7

Astellas Pharma Inc.-Key Company Facts 8

Astellas Pharma Inc.- Company Description 9

Astellas Pharma Inc.- Top Executives 10

Astellas Pharma Inc.- Head Office & Locations 12

Head Office - Country 12

Astellas Pharma Inc.- Productsand Services 13

Products 13

Services 14

Astellas Pharma Inc.- Corporate Strategy 15

Astellas Pharma Inc.- Business Description 18

Immunology Segment 19

Urology Segment 20

Oncology Segment 20

Astellas Pharma Inc.- ESG Spotlight 21

Environment 22

Social 22

Corporate Governance 22

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Astellas Pharma Inc.- SWOT Analysis	24
Overview	24
Strengths	26
Weaknesses	30
Opportunities	31
Threats	33
Astellas Pharma Inc.- PESTLE Analysis	34
Overview	34
Political Factors	36
Economic Factors	38
Social Factors	39
Technological Factors	41
Legal Factors	43
Environmental Factors	44
Astellas Pharma Inc.- Financial Deep Dive	45
Share Price Trend - Nov-2023 to Nov-2024 (Average Share Closing Price)	45
Profit and Loss Statement	47
Summary of Profit and Loss Statement	47
Balance Sheet	49
Summary of Balance Sheet	49
Cash Flow Statement	51
Summary of Cash Flow Statement	51
Key Financial Ratio Analysis	53
Astellas Pharma Inc.- Ratio Charts	54
Activity Ratio Charts	54
Growth Ratios Charts	55
Leverage Ratio Charts	56
Liquidity Ratio Charts	57
Profitability Ratio Charts	58
Competing Players	59
Snapshot of Competing Players	60
Johnson & Johnson	60
Key Company Facts	60
Company Description	60
Novartis AG	61
Key Company Facts	61
Company Description	61
Pfizer Inc.	62
Key Company Facts	62
Company Description	62
Merck & Co., Inc.	63
Key Company Facts	63
Company Description	63
GlaxoSmithKline Pharmaceuticals Ltd	64
Key Company Facts	64
Company Description	64
Astellas Pharma Inc. - In the News	65

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

28-Oct-2024 -Astellas Provides Update on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the European Union	65
25-Oct-2024 -Every Day of Vision Loss Is One Too Many: Addressing the Impact of Eye Diseases	66
21-Oct-2024 -stellas' VYLOYTM (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer	66
18-Oct-2024 -Silence, Stigma, and Misunderstanding: Our Mission to Break Down Barriers in Menopause	68
10-Oct-2024 -Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause	70
08-Oct-2024 -Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications	71
30-Sep-2024 -Notice Regarding Foreign Exchange Loss	72
24-Sep-2024 -Japan's Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma	72
30-May-2024 -U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE	74
21-May-2024 -Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	76
19-May-2024 -Patient Centricity and AI: Navigating the Promise and Pitfalls	77
15-May-2024 -Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme	80
Appendix	81
Definitions	81
SWOT Analysis	81
PESTLE Analysis	81
Value Chain Analysis	81
ESG Spotlight	81
Financial Deep Dive	81
Financial Ratios-	82
Activity Ratios	82
Growth Ratios	83
Leverage Ratios	84
Liquidity Ratios	85
Market Ratios	86
Profitability Ratios	86
Research Methodology	87
Disclaimer	88
Contact Us	88

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Astellas Pharma Inc. (4503:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends

Company Report | 2024-11-22 | 88 pages | Quintel Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$175.00
	Multi User Price	\$195.00
	Enterprise User Price	\$225.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-08

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com